ASSOCIATION OF SERUM LEPTIN WITH INSULIN RESISTANCE IN KYRGYZ ETHNIC GROUP
DOI:
https://doi.org/10.54890/.v3i3.1193Abstract
Aim: evaluation of relationship between serum leptin and insulin resistance (IR) in the group of ethnic Kyrgyzes.
Material and methods: ethnic Kyrgyzes, native inhabitants of Kyrgyz Republic, older than 30 years were included in this study. All patients undergone survey included complaints and anamnesis; general investigation with measurements of blood pressure, anthropometric parameters (height, weight, waist (WC) and hip circumference (HC)). Body mass index (BMI) was calculated as: BMI= weight (kg) / height (м)2. Abdominal obesity was established at WC≥102cm in male and WC≥88cm in female. BMI≥30кг/м2 was assessed as obesity. Laboratory investigations included analysis of plasma glucose (fasting), serum insulin and leptin. IR index HOMA was calculated by formula: НОМА=serum insulin (μIU/ml) х plasma glucose (mmol/l) /22,5. Values of index HOMA≥2,77 were assessed as IR. Results: 322 ethnic Kyrgyzes (145 males, 177 females) at age 30-70 years (51,7 ± 9,6). were included in this study. All patients were stratified by 4 groups accordingly leptin quartiles (male: <2,2; 2,2-4,2; 4,3-6,34; >6,34нг/мл; female: <8,05; 8,05-13,4; 13,5-19,09; >19,09ng/ml). Patients from upper quartiles had higher levels of BMI, WC and serum glucose, compare with lower quartiles. The IR frequency was higher in patients from 3rd and 4th quartiles, than 1st and 2nd quartiles (p<0,0001 – both sexes). In male and female patients serum leptin significantly correlated with glucose (p<0,01), index НОМА (p<0,0001) and IR (p<0,0001).
Conclusion: serum leptin associated with IR in group of ethnic Kyrgyzes.
Keywords:
insulin resistance, leptin, HOMA index.References
1. Sattar N, Gaw A, Scherbakova O, et al. Metabolicsyndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414–19.
2. Grundy SM, Hansen B, Smith SC, et al. Clinicalmanagement of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004;109:551–6.
3. Ukkola O, Bouchard C. Clustering of metabolicabnormalities in obese individuals: The role of genetic factors. Ann Med 2001;33:79–90.
4. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595–1607.
5. Bergman RN, Kim SP, Hsu IR, et al. Abdominal obesity:role in the pathophysiology of metabolic disease and cardiovascular risk. Am J Med 2007;120:S3–S8; discussion S29–S32.
6. Correia ML, Haynes WG. Leptin, obesity andcardiovascular disease. Curr Opin Nephrol Hypertens 2004;13:215–23.
7. Altman J. Weight in the balance. Neuroendocrinology2002; 76: 131-6.
8. Trayhurn P, Bing C, Wood IS. Adipose tissue andadipokines – energy regulation from the human perspective. J Nutrition 2006; 136: 1935S-9S.
9. Lindstrom J, Tuomilehto J. The diabetes risk score: apractical tool to predict type 2 diabetes risk. Diabetes Care 2003; 26: 725–31.
10. Mantzoros CS. The role of leptin in human obesity anddisease: A review of current evidence. Ann Intern Med 1999;130:671–80.
11. Emilsson V, Liu YL, Cawthorne MA, et al. Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. Diabetes 1997;46:313-6.
12. Van Gaal LF, Wauters MA, Mertens IL, et al. Clinical endocrinology of human leptin. Int J Obes Relat Metab Disord 1999;23(Suppl 1):29-36.
13. Huang KC, Lin RC, Kormas N, et al. Plasma leptin isassociated with insulin resistance independent of age, body mass index, fat mass, lipids, and pubertal development in nondiabetic adolescents. Int J Obes Relat Metab Disord 2004;28:470–5.
14. Galletti F, Barbato A, Versiero M, et al. Circulating leptin levels predict the development of metabolic syndrome in middle-aged men: An 8-year follow-up study. J Hypertens 2007;25:1671–7.
15. Franks PW, Brage S, Luan J, et al. Leptin predicts aworsening of the features of the metabolic syndrome independently of obesity. Obes Res 2005;13:1476–84.
16. Lin JD, Chiou WK, Chang HY, et al. Serum uric acid andleptin levels in metabolic syndrome: A quandary over the role of uric acid. Metabolism 2007;56:751–6.
17. Hodge AM, Boyko EJ, de Courten M, et al. Leptin andother components of the Metabolic Syndrome in Mauritius—a factor analysis. Int J Obes Relat Metab Disord 2001;25:126–131.
18. Patel SB, Reams GP, Spear RM, et al. Leptin: linkingobesity, the metabolic syndrome, and cardiovascular disease. Curr Hypertens Rep 2008;10:131-7.
19. Wallace AM, McMahon AD, Packard CJ, et al. Plasmaleptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001;104:3052-6.
Downloads
Published
How to Cite
Issue
Section
